Epidemiological studies suggest that HSV-2 increases the risk of HIV-1 acquisition. 1, 2, 3 In populations with HSV-2 prevalence of 80%, nearly 50% of HIV-1 infections are attributable to an HSV-2 ...

Persons who have tested positive for herpes simplex virus type 2 (HSV-2) but do not have symptoms or genital lesions still experience virus shedding during subclinical (without clinical manifestations ...

Ex vivo analysis of these cells allows unbiased characterization of the cellular composition, function, and phenotype of the local T-cell response to HSV-2. In the present study, we obtained cervical ...

Vaccines are one of the most important medical inventions of modern times that have saved and enhanced innumerable lives around the world. Despite the technological advances in vaccine design and ...

March 15, 2010 (Atlanta, Georgia) — Rates of herpes simplex virus (HSV)-2 infection have remained stable for the past decade, but approximately 1 in 6 people 14 to 49 years of age is infected, ...

Herpes simplex virus 2 (HSV-2) is a sexually transmitted infection that can cause painful, recurrent lesions in the genital skin and mucosa. HSV-2 initially infects genital epithelial cells before ...

(HealthDay News) — The novel herpes simplex virus (HSV) helicase-primase inhibitor pritelivir is more effective than valacyclovir for reducing genital HSV-2 shedding, according to a study published in ...

COBAS ANALYZER for use with Elecsys HSV-1 IgG and HSV-2 IgG Assays by Roche Roche announced that it has received clearance from the FDA for its IgG Antibody to herpes simplex virus (HSV) types 1 and 2 ...

Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage biotechnology company, today announced a strategic partnership ...

Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. | Italian ...

Serum YKL-40 levels in patients with cervical cancer are elevated compared to patients with cervical intraepithelial neoplasia and healthy controls No significant financial relationships to disclose.